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Background: We previously reported that approximately one-fourth of patients with lymphangio-
leiomyomatosis (LAM) may respond to therapy with bronchodilators. However, the validity of
those observations has been questioned. The aims of the present study were to determine the
prevalence of reversible airflow obstruction in patients with LAM and to identify associated
clinical and physiologic parameters.
Methods: First, the clinical and physiologic characteristics of 235 patients were analyzed to
determine the frequency of the response to albuterol during a total of 2,307 visits. Second, we
prospectively evaluated the response to albuterol (2.5 mg) and ipratropium (500 g) in 130
patients, and correlated their responses with their clinical and physiologic characteristics.
Results: In the retrospective study, 51% of the patients responded at least once to bronchodila-
tors; of these, 12% responded > 50% of the time. A higher frequency of positive bronchodilator
responses was associated with greater rates of decline in FEV1 and diffusing capacity of the lung
for carbon monoxide (DLCO). In the prospective study, 39 patients (30%) responded to broncho-
dilators, including 12 to ipratropium, 9 to albuterol, and 18 to both. The prevalence of asthma and
smoking in the 39 responders was not different from that seen in the 91 nonresponders. Patients
who responded to ipratropium, albuterol, or both had significantly (p < 0.02) lower FEV1 and
DLCO, and a greater rate of FEV1 decline (p  0.044) and DLCO decline (p  0.039) than patients
who did not respond to these bronchodilators. After adjusting for FEV1/FVC ratio, DLCO decline
also was greater in responders than in nonresponders (p  0.009).
Conclusions: Patients with LAM may have partially reversible airflow obstruction. A positive
response to bronchodilators is associated with an accelerated rate of decline in pulmonary
function. (CHEST 2009; 136:1596–1603)
Abbreviations: Dlco  diffusing capacity of the lung for carbon monoxide; LAM  lymphangioleiomyomatosis;
NIH  National Institutes of Health; RV residual volume; TLC  total lung capacity
L ymphangioleiomyomatosis (LAM) is a multisys-tem disease that predominantly affects women.
It is characterized by the proliferation of abnormal
smooth muscle-like cells (LAM cells) that lead to the
formation of lung cysts, fluid-filled cystic structures
in the axial lymphatics (eg, lymphangioleiomyomas),
and abdominal tumors (eg, angiomyolipomas),1–5
which occur sporadically or in association with tu-
berous sclerosis complex.6–8 Pulmonary function
tests show reduced FEV1 and diffusing capacity of
the lung for carbon monoxide (Dlco).5
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We previously reported9 that one-fourth of 143
patients with LAM frequently exhibited a positive
response to -adrenergic bronchodilators, which was
associated with more severe airflow obstruction and
greater rate of decline in expiratory flow. A subse-
quent smaller study by Yen et al,10 however, con-
cluded that reversible airflow obstruction is very rare
in LAM patients, which prompted us to revisit this
matter. In addition, we questioned whether the type
of bronchodilator used could affect the frequency of
a positive response. To address these issues, we first
expanded our retrospective analysis9 to 235 patients.
Then, we conducted a prospective study in 130
patients to determine the prevalence of positive
responses to both -adrenergic and anticholinergic
agents. The primary aim of this study was to deter-
mine the frequency and the factors associated with a
positive response to these two families of broncho-
dilators.
Materials and Methods
Study Populations
For the retrospective analysis, the population comprised 235
patients with LAM who had at least five visits to the National
Institutes of Health (NIH) [National Heart, Lung, and Blood
Institute Protocol 95-H-0186]. For the prospective study, the
population consisted of 106 patients participating in the same
protocol at NIH (Bethesda, MD) and 24 patients who were
followed up at the Ospedale San Giuseppe (Milan, Italy). Phys-
iologic data from 21 of the 106 NIH patients participating in the
prospective study were reported previously.9 The study was
approved by the Institutional Review Board of the National
Heart, Lung, and Blood Institute, NIH; Office of Human
Subjects Research, NIH; and Ospedale San Giuseppe, which
had a Federal-Wide Assurance with the US Office of Human
Research Protections. Written consent was obtained from all
patients.
Study Design
Pulmonary function tests were performed according to Amer-
ican Thoracic Society/European Respiratory Society stan-
dards.11,12 On day 1 of the prospective study, flow rates (Master
Screen PFT; Erich Jaeger; Wuerzburg, Germany) for the patients
were measured before and after nebulization with 2.5 mg of
albuterol (or ipratropium). On the following day (day 2) and at
the same time of day, flow rates were measured before and after
nebulization of 500 g of ipratropium (or albuterol). The order of
drug testing was random. Patients abstained from using inhaled
bronchodilators and corticosteroids for 12 h prior to testing. A
positive response to bronchodilators consisted of an increase in
FVC or FEV1 of  12% over the baseline and of at least 200
mL.13 Because the diagnosis of asthma may be difficult to
establish in a patient with airflow obstruction caused by LAM, we
relied on a history of asthma present during childhood or
adolescence prior to the onset of LAM to determine whether a
patient could have coexisting asthma.
Chest Roentgenograms and CT Scans
The severity of lung disease was graded by CT scans, as
previously described.14
Statistical Analysis
The yearly rate of change in percent predicted FEV1 and
Dlco was estimated as previously reported.15 Univariate and
multivariate regression analyses were performed to identify
factors related to the pulmonary function rate of decline.15
Analysis of variance and regression methods were used to
compare lung function, lung involvement by CT scan, broncho-
dilator response, and functional decline. The bronchodilator
response was considered both as a continuous measurement and
as a categorical variable (never, response in  50% of visits, or
response in  50% of the visits).
To identify the factors associated with a response to broncho-
dilators in the prospective study, we analyzed the data using the
following response variables: response to albuterol; response to
ipratropium; response to any bronchodilator (binary outcome);
and response to the number of bronchodilators (three-category
response, 0, 1, or 2). The explanatory variables considered were
as follows: age; various pulmonary function tests, including FEV1,
Dlco, and FEV1/FVC ratio; the number of years of previous
follow-up; and the yearly rate of change for FEV1 and Dlco. For
each response variable, we identified all explanatory variables
that were associated with the response at the 0.10 significance
level in a univariate analysis using a t test or a trend test
(Jonckheere-Terpstra test) for the three-category response vari-
able; these variables then were considered for inclusion in a
multivariate logistic regression. All tests were two sided. The data
are reported as the mean SEM.
Results
Retrospective Study
Age and pulmonary function data of the popula-
tion are listed in Table 1. Of the study population,
211 were white, 13 were African American, 9 were
Asian, and 2 were Hispanic. The number of visits per
Table 1—Age, Lung Function, and Yearly Change in
FEV1 and DLCO in 235 Patients With LAM
Variables Values
Age, yr 50.4  0.6 (25 to 82)
Visits, No. 9.8  0.3 (5 to 22)
TLC, % predicted 93.0  1.0 (56 to 141)
FRC, % predicted 95.7  1.2 (28 to 144)
RV, % predicted 99.2  1.9 (27 to 241)
RV/TLC ratio, % 36.1  0.5 (10 to 68)
FVC, % predicted 89.7  1.1 (44 to 133)
FEV1, % predicted 78.3  1.5 (26 to 132)
FEV1/FVC, % 67  1 (21 to 94)
Dlco, % predicted 76.1  1.6 (26 to 139)
Change in FEV1/yr, mL 83.1  5.9 (684 to 154)
Change in FEV1/yr, % 2.4  0.2 (28 to 6)
Change in Dlco/yr, mL/min/mm Hg 0.71  4.7 (7.3 to 0.9)
Change in Dlco/yr, % 3.0  0.2 (31 to 5)
Values are presented as the mean SEM (range). FRC  functional
residual capacity.
www.chestjournal.org CHEST / 136 / 6 / DECEMBER, 2009 1597
patient was 9.8  0.3 (range, 5 to 22), for a total of
2,307 visits. The response to a -adrenergic bron-
chodilator was tested at all visits.
Bronchodilator Response, Severity of Lung Disease,
and Decline in Lung Function
Twenty-eight patients (12%) responded to albu-
terol at  50% of the visits, 93 patients (40%)
responded  50% of the time, and 114 patients
(48%) never responded (Table 2). Patients who
responded to bronchodilators  50% of the visits
had significantly lower FEV1 (p  0.01) than those
who responded  50% of the time and those who
never responded. Patients who ever responded to
bronchodilators had a lower Dlco (p  0.05) than
those who never responded. Further, patients who
responded to bronchodilators at  50% of the visits
had greater rates of FEV1 decline (p 0.01) and
Dlco decline (p  0.05) than those in the other two
groups (Table 2). Conversely, those who never
responded had better lung function and slower
rates of functional decline. We found a significant
relationship between the percentage of positive
responses to albuterol and the yearly rate of
change in FEV1 (r  0.368; p  0.0001) and
Dlco (r  0.209; p  0.001) [Fig 1, 2].
Decline in Lung Function and Use of
Bronchodilators and Corticosteroids
Of the 235 patients studied, 115 used -adrenergic
or anticholinergic bronchodilators regularly; 59 of
the 115 patients also used inhaled corticosteroids.
Table 2—Mean Pulmonary Function Values and Yearly Change in FEV1 and DLCO in 235 Patients With LAM
Divided According to Bronchodilator Response
Bronchodilator Response Never  50% of Visits  50% of Visits
Patients, No. 114 93 28
Dlco, % 82.5  2.2* 70.9  2.6 67.1  4.3
FEV1, % 87.7  2.0* 72.4  2.2* 60.0  3.8*
Change in FEV1/yr, mL 61.3  5.1* 90.5  9.3* 147.1  29.4*
Change in FEV1/yr, % 1.5  0.2* 2.8  0.4* 5.0  1.1*
Change in Dlco/yr, mL/min/mm Hg 0.63  0.07 0.71  0.05 1.03  0.15*
Change in Dlco/yr, % 2.6  0.3 3.0  0.3 4.6  0.7*
Values are presented as the mean  SEM.
*Values are significantly different from the other two groups (analysis of variance).
Figure 1. Relationship between the percentage of positive responses to bronchodilators and the yearly
rate of change in percent predicted FEV1 (r  0.368; p  0.0001).
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Patients who were treated with bronchodilators had
lower FEV1 (p  0.001) and Dlco (p  0.001), and
greater rates of FEV1 decline (p  0.02) and Dlco
decline (p  0.012) than those who were not treated
with bronchodilators. In addition, they were more
likely to have a positive bronchodilator response than
those who did not use bronchodilators. This finding
could be due to the tendency of physicians to
prescribe these agents to patients with poor function
and positive bronchodilator response. However,
other factors may explain the greater rates of decline
in lung function seen with patients who are receiving
therapy with bronchodilators. Because within the
three bronchodilator response categories (ie, never,
 50%, and  50%) no significant differences in the
rates of decline of FEV1 and Dlco were found
between those who used bronchodilators and those
who did not, it appears that lung function decline is
not worsened or improved by the use of bronchodi-
lators.
Factors Affecting the Rate of Decline in Lung
Function
A greater rate of FEV1 decline was associated with
more lung involvement by CT scan, more frequent
bronchodilator response (continuous measure),
lower FEV1 and Dlco, younger age, and larger
cysts. The rate of decline of Dlco was significantly
associated with bronchodilator response and age
(p  0.022). These variables, along with an interac-
tion term of CT scan grade and bronchodilator
response, were included in a multivariate analysis
(n  220). The interaction term was statistically
significant (p  0.05); therefore, we presented the
data in Table 3 by CT scan grade. As shown in
Table 3, bronchodilator response (p  0.001), age
(p  0.007), and cyst size (p  0.046) were found to
be significant predictors of the rate of decline of
FEV1 in those patients in CT scan grade I (n  101).
Bronchodilator response (p 0.003) and initial
Dlco (p  0.04) were significant predictors of
Dlco decline in these patients (Table 3). Broncho-
dilator response also was a significant predictor of
FEV1 decline (p 0.002) in patients in CT scan
grade II (n  52). In patients in CT scan grade III
(n  67), bronchodilator response was not a predic-
tor of FEV1 or Dlco decline.
Prospective Study
Age and pulmonary function data are shown in
Table 4. Of the 130 patients, 118 were white, 4 were
African American, 6 were Asian, and 2 were His-
panic. The diagnosis of LAM was made from a lung
biopsy specimen (n  72) or CT scan (n  58) a
mean time of 6.1  0.4 years prior to testing. The
Italian cohort was significantly younger than the
NIH cohort (38.2 1.9 vs 46.6 0.8 years, respec-
tively; p 0.0001) and had significantly lower FEV1
(59.4% 5.1% predicted vs 74.4% 2.5% predicted,
respectively; p 0.010) and Dlco (53.0%  4.9%
Figure 2. Relationship between the percentage of positive responses to bronchodilators and the yearly
rate of change in percent predicted Dlco (r  0.209; p  0.001).
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predicted vs 67.8%  2.3% predicted, respectively;
p  0.02). Disease duration also was shorter, but the
difference was not statistically significant (5.8  0.9
years vs 7.5 0.5 years, respectively; p 0.103).
Response to Bronchodilators
Thirty-nine patients (30%) responded at least once
to bronchodilators as follows: 9 patients responded to
albuterol; 12 patients responded to ipratropium; and
18 patients responded to both. Ninety-one patients
were nonresponders. In 21 of the 39 responders, we
had prior data regarding their response to albuterol
that showed that only 2 responders had not exhibited
prior positive responses to albuterol. Conversely, in
the 48 of the 91 nonresponders in whom the results
of prior responses to albuterol were available, only 4
were found to have had positive albuterol responses.
Because the Italian patients were younger, had
more advanced disease, and had a shorter duration
of their conditions, we evaluated the frequency of
bronchodilator response in this cohort. We found
that 9 of the 24 patients (37.5%) responded to at
least one of the two bronchodilators, 5 patients
responded to both, 1 patient responded only to
albuterol, and 3 patients responded only to ipratro-
pium. The rates of FEV1 and Dlco decline for these
patients were not available.
Coexistence of Asthma, Cigarette Smoking, and
Use of Bronchodilators and Corticosteroids
Among the 39 responders, 2 had a history of
asthma, 14 had a history of allergies, and 8 were
ex-smokers. Among the 91 nonresponders, 5 had a
history of asthma, 36 had a history of allergies, and
23 had a positive history for smoking. Forty-eight of
the 130 patients, of whom 22 were responders, used
bronchodilators regularly; 24 of the 48 patients also
used steroids. Patients who used bronchodilators had
lower FEV1 than those who did not (64.2% 3.9%
predicted vs 82.1%  3.5% predicted; p  0.0008)
as well as lower Dlco (61.2%  3.5% predicted vs
72.4%  3.4% predicted; p  0.024). The rates of
lung function decline were available in 93 of the 130
patients. As in the case of the retrospective study,
there was no statistically significant difference between
bronchodilator users (n 44) and nonusers (n 49) in
the rates of FEV1 decline (2.5% 0.8% predicted vs
2.7%  0.4% predicted, respectively; p  0.77)
and Dlco decline (3.7%  1.1% predicted vs
4.7%  0.9% predicted, respectively; p  0.47).
Response to Bronchodilators, Severity of Disease,
and Rate of Functional Decline
Responders had lower FEV1 and Dlco, and
larger residual volume (RV) than nonresponders (Fig
3). We found that in the 93 patients in whom
longitudinal data spanning a mean duration of
3.4  0.3 years were available, the rate of FEV1
decline was significantly greater in the 31 responders
than in the 62 nonresponders (4.0% 0.9% predicted
vs 1.9% 0.3% predicted, respectively; p 0.044).
The decline in Dlco also was significantly greater
in responders than in nonresponders (6.9% 1.8%
predicted vs 2.8%  0.5% predicted, respectively;
p  0.039). Univariate analyses showed that a re-
Table 4—Pulmonary Function Data in 130 Patients
With LAM
Variables Values
Age, yr 45.1  0.8
TLC, L 4.86  0.08 (95.0  1.4)
FRC, L 2.76  0.06 (99.0  2.1)
RV, L 1.89  0.06 (110.3  3.3)
RV/TLC ratio, % 38.4  0.9
FVC, L 2.98  0.06 (87.4  1.6)
FEV1, L 1.90  0.06 (71.6  2.2)
FEV1/FVC ratio, % 63.0  1.4
Dlco, mL/min/mm Hg 14.0  0.4 (65.1  2.1)
Data are presented as the mean  SEM (% predicted).
Table 3—Significant Predictors of Rates of Decline in FEV1 and DLCO According to CT Scan Grade of Disease
Severity
Predictors
Rate of Decline in FEV1 Rate of Decline in Dlco
Grade I Grade II Grade III Grade I Grade II Grade III
BDR 0.061 ( 0.001) 0.068 (0.002) 0.050 (0.003) 0.070 ( 0.001)
Age 0.094 (0.007) 1.640 ( 0.001) 0.090 (0.002)
Initial FEV1 0.041 (0.009) 0.059 (0.005)
Initial Dlco 0.030 (0.041)
Cyst size 1.960 (0.046)
Values are the parameter estimates (p value) for significant predictors (p 0.05) of FEV1 and Dlco decline in the regression model. Within each
column, the reported values are adjusted for the significant variable shown in that column. BDR  positive bronchodilator response (a continuous
measure of the percentage response over all visits).
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ponse to albuterol was associated with a greater rate
of decline in percent predicted FEV1 (p  0.047)
and Dlco (p  0.034). A positive response to ipra-
tropium was associated only with the initial percent
predicted FEV1 (p  0.001). A positive response to
either bronchodilator was associated with a lower
percent predicted FEV1 (p  0.0003) and Dlco
(p  0.016), and greater rates of decline in percent
predicted FEV1 (p  0.041) and Dlco (p  0.043).
Multivariate analysis showed that after adjusting for
FEV1/FVC ratio, a response to albuterol, but not to
ipratropium, was associated with a greater rate of
decline in percent predicted Dlco (p  0.004).
Similarly, a response to either of the bronchodilators
was associated with a greater decline in percent
predicted Dlco (p  0.009).
A trend analysis showed that the rate of decline in
either FEV1 or Dlco is associated with whether a
patient was responding to zero, one, or two broncho-
dilators. A trend for greater rate of decline in FEV1
and Dlco is associated with a positive bronchodila-
tor response. Younger patients with a greater rate of
decline in FEV1 (p  0.018) and Dlco (p  0.007)
were more likely to respond to both bronchodilators
(Fig 4). Multivariate analysis showed that FEV1/FVC
ratio (p  0.0001) and age (p 0.005) were the only
significant predictors of a bronchodilator response.
Discussion
Our retrospective analysis showed that a greater
frequency of a positive bronchodilator response to
-adrenergic bronchodilators was associated with
worse lung function and a greater rate of decline in
FEV1 and Dlco. Although patients with worse lung
function were more likely to be treated with bron-
chodilators, we found no evidence that the use of
these agents changed the rate of decline in lung
function.
The prospective study confirmed that responders
to bronchodilators have greater rates of FEV1 and
Dlco decline. Further, a positive response to bron-
chodilators was a predictor of decline in Dlco after
adjusting for FEV1/FVC ratio. This finding differs
from those reported in our previous study9 in which
we found a relationship between a positive broncho-
dilator response to albuterol, the predominance of
LAM cell proliferation, and an accelerated decline in
FEV1 but not in Dlco. However, the fact that a
response to bronchodilators is now shown to be
associated with a greater rate of Dlco decline is not
surprising. Cyst formation in LAM patients is related
to the proliferation of LAM cells and their produc-
tion of toxic products16–19; consequently, a greater
decline in Dlco caused by new cyst formation
would be anticipated. Indeed, LAM cells are clus-
tered in nodules that line the cysts.20 Within the
LAM nodules, regions of the basement membrane,
and particularly the elastic fibers and collagen fibrils,
are disrupted, which could lead to lung tissue de-
struction and impairment of gas exchange.16–19
The pathophysiology of airflow obstruction in
LAM patients has yet to be fully characterized. The
old model21 postulated that airflow obstruction was
due to the loss of support of small airways, with
resultant collapse during expiratory flow. An excess
of airway mural smooth muscle was not considered
as important. However, changes in lung elastic recoil
Figure 3. Prospective study: percent predicted FEV1, RV, and
Dlco in patients who showed a positive response to at least one
of two bronchodilators (white bars) and those who had no
response (black bars). Responders had lower FEV1 and Dlco,
and higher RV than nonresponders. *  p  0.05.
Figure 4. Prospective study: median and interquartile range for
age and yearly changes in Dlco and FEV1 according to the
response to bronchodilators. The upper and lower limits of the
box represent the 75th and 25th percentiles, and the line inside
the box represents the median. The upper and lower ends of the
“whiskers” represent the 95th and 5th percentiles. Age is based
on the whole sample, but the yearly rate of change of percent
predicted Dlco and FEV1 is based only on the NIH patients.
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do not appear to be an important mechanism of
airflow obstruction in LAM.22 Instead, decreased
expiratory flow results from an increase in airways
resistance caused by the proliferation of LAM cells
surrounding the airways. In agreement,9 the propor-
tion of positive responses to -adrenergic broncho-
dilators was found to be greater in patients whose
lung biopsy specimens showed a predominantly pro-
liferative pattern of LAM lesions. Further, although
airways inflammation (ie, bronchiolitis) was found in
airways surrounded by heavy infiltrates of LAM
cells,9 there was no pathologic evidence of bronchial
asthma, smooth-muscle hypertrophy, or any other
condition that could be associated with airways
disease. One must conclude that airflow obstruction
in patients with LAM is related to LAM cell prolif-
eration. Some evidence in favor of this interpretation
is found in the report by Bissler et al,23 who showed
that sirolimus improves flow rates and airtrapping in
patients with LAM. This effect occurred without any
changes in total lung capacity (TLC), Dlco, or CT
scan volume of lung cysts, suggesting that the
number of LAM cells surrounding the airways was
diminished by sirolimus therapy and this effect
improved airflow. Alternatively, LAM lung nodules,
which are infiltrated by mast cells and contain mast
cell mediators,24 could secrete compounds that en-
hance airway reactivity.
The different frequency of response to -adrener-
gic and anticholinergic agents observed in this study
could be due to a preferential response to one family
of bronchodilators or caused by spontaneous daily
variations in the grade of airflow obstruction. It is
also possible that those patients who were using
bronchodilators and corticosteroids with metered-
dose inhalers may have become desensitized to the
effects of either family of bronchodilators, and with-
holding these drugs for 12 h prior to testing may not
have been sufficient to eliminate the effect of these
therapies. We have not studied the potential roles of
neural pathways in determining the bronchodilator
response. Contrasting with the adrenergic agents,
the bronchodilator effects of anticholinergic agents
may favor the large airways rather than the small
airways.25 Regardless of the site of action of bron-
chodilators, as in other lung diseases,26 some patients
with LAM may respond more favorably to one or the
other category of drugs.
Our finding that patients who respond to broncho-
dilators appear to have a greater rate of decline in
FEV1 and Dlco needs to be interpreted with
caution. Indeed, the possibility that the associations
of a positive bronchodilator response, more severe
lung disease, and a greater rate of functional decline
may be due to a positive response to bronchodilators
is more likely to be observed in patients with more
severe airflow limitation who progressed more
quickly cannot be excluded. However, in our retro-
spective study, we found no difference in disease
duration between those who responded to broncho-
dilators during 50% of the visits (12.9  1.2 years),
those who never responded (11.7  0.6 years), and
those who responded during  50% of the visits
(14.5  0.8 years).
The possibility that our studies may underestimate
the prevalence of airflow obstruction reversibility in
LAM also cannot be discounted. Indeed, the concept
that patients with airflow obstruction who show a
positive response to bronchodilators at one testing do
so consistently is not supported by the literature,
even in patients with asthma. Guyatt et al27 found
that in patients with chronic airflow obstruction, the
reproducibility of short-term change in FEV1 over
three repetitions was poor. Others28 have shown that
changes in FEV1 (or FVC) of  12% and 200 mL
over baseline, as recommended by American Thoracic
Society/European Respiratory Society criteria,13 may
actually underestimate the prevalence of a positive
response. Indeed, some29,30 have suggested that the
criteria for determining a positive response to bron-
chodilators be changed. Patients with an FEV1 1.5
L may not ever reach the 200-mL increase in FEV1,
and those with an FEV1 of  3 L may not reach the
12% increase mark.30 In fact, the short-term bron-
chodilator response may have limited value in
separating patients with asthma from those with
COPD.31
From our study, we conclude that a significant
number of patients with LAM have partially revers-
ible airflow obstruction, which may predict a more
rapid decline in function. Although we found no
evidence that bronchodilator use changes the rate of
decline in lung function, treatment with bronchodi-
lators probably should be undertaken in patients
with LAM who have evidence of airflow obstruction.
Furthermore, as lung function deteriorates, patients
may show a positive response to bronchodilators.
Therefore, it is important to monitor lung function
not only to evaluate disease progression and the
response to bronchodilators, but also to optimize
therapy. In this regard, it is also important to test the
effectiveness of different families of bronchodilators.
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